Source Search Page
Revolutionizing Cancer Care With Genomic Testing
17+ hour, 8+ min ago —...Bartlett, MD, discussed the utilization and growing importance of... ...Bartlett, MD Thanks to advances in genomic testing, experts can now... ...Bartlett, chair of the Allegheny Health Network Cancer Institute... ...The original Cancer Genome Project and Human Genome Project took...
New Allo-HCT Approach Boosts Immune Response, Survival
15+ hour, 12+ min ago —...Michael Scordo, MD, discussed findings from a phase 2 study investigating... ...late-breaking abstract presented at the 2024 Transplantation and Cellular Therapy... ...specialist and cellular therapist at Memorial Sloan Kettering Cancer... ...According to Michael Scordo, MD, the model successfully achieved...
The Role of Circulating Tumor DNA in Bladder Cancer
1+ day ago —...Siefker-Radtke, MD, looked at the newer treatment strategies available... ..., MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating... ..., Stephen Williams, MD, discussed a retrospective cohort study analyzing... ...Adjuvant Therapy in Bladder Cancer: Real-World vs Clinical Trials Alex Chehrazi-Raffle...
EV-302 Study Design and Results
1+ day ago —...Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss... ...Siefker-Radtke, MD, looked at the newer treatment strategies available... ..., Stephen Williams, MD, discussed a retrospective cohort study analyzing... ...Adjuvant Therapy in Bladder Cancer: Real-World vs Clinical Trials Alex Chehrazi-Raffle...
PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment
1+ day ago —...The first arm of the phase 2 PROSPECT study evaluating tirabrutinib... ...NCT04947319), which is evaluating the efficacy and safety of tirabrutinib... ...executive officer of ONO PHARMA USA, in a press release.... ..., executive officer, executive director, clinical development of...
PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer
1+ day ago —...Associate Professor, Clinical Research Division, Fred Hutch Division... ...During a Case-Based Roundtable® event, David Zhen, MD, discussed... ...Even if you come to our GI group in the Fred Hutchinson Cancer Center... ...Moehler M, Xiao H, Blum SI, et al....
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
1+ day ago —...Bhavana Pothuri, MD, and Krishnansu S.... ...In separate virtual live events, Bhavana Pothuri, MD, and Krishnansu... ...During a Case-Based Roundtable® event, Saby George, MD, discussed... ...patients who could receive allogeneic stem cell transplant. 2 Commerce Drive...
New Combination Shows Strong Responses in Phase 2a Portion of AML Trial
1+ day ago —...Life Sciences Group, Inc.... ...twice weekly, exceeding the targeted 20% rate.1 At the same time, SELLAS... ...FDA Lifts Clinical Hold on CAR T Study in AML The phase 1 study of... ...FDA Halts Clinical Studies of Magrolimab in AML, MDS Magrolimab will...
Identifying NTRK and RET Alterations in Differentiated Thyroid Cancer
2+ day ago —...Lova Sun, MD, discusses genetic alterations in thyroid cancer, including... ...(around 50% of cases), RET (10%-20%), and NTRK (2%-4%).... ...Here, Lova Sun MD, MCSE, assistant professor of medicine at the Hospital... ...In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed...
Regorafenib Continues to Benefit Patients With Advanced CRC
2+ day ago —...oncologist, and associate professor at the Mayo Clinic in Phoenix... ...Ahn, DO, medical director of the clinical cancer research office,... ...In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS... ...multiple myeloma in the first article of a 2-part series. 2 Commerce Drive...